ISSN:
1600-0625
Source:
Blackwell Publishing Journal Backfiles 1879-2005
Topics:
Medicine
Notes:
Abstract 15-hydroxyeicosatrienoic acid, 15-HETrE, the 15-lipoxygenase product of dihomogammalinolenic acid (DGLA), can inhibit the biosynthesis of the proinflammatory eicosanoids leukotriene B4 (LTB4) and 12-hydroxyeicosatctraenoic acid (12-HETE). The purpose of the present study was to investigate the incorporation of [I4C] 15-HETrE in specific membrane phospholipids of cultured human keratinocytes in vitro. [I4C] 15-HETrE was rapidly incorporated into keratinocytes. When a plateau was reached after 3 hours, 15% of the added radioactivity was incorporated into lipids; 96.5% into phospholipids (PL) and 3.5%. into neutral lipids (NL). Within the phospholipid classes, [I4C]15-HETrE showed selectivity for incorporation into phosphatidylinositol (PI). The mean proportion of [I4C] 15-HETrE in the PI, phosphatidylcholin (PC) and phosphatidyle-thanolamin (PE) was 83.2%, 8.5% and 8.3%, respectively. We then investigated the incorporation of 15-HETrE in epidermal phospholipids of psoriatic skin intralesionally injected with 15-HETrE. Four patients took part in the study. In each patient four identical plaques were injected with 0.65 ml of 2.0 µM, 6.2 µM, 18.6 µM of 15-HETrE (0.4 µg, 1, 2 µg and 3.6 µg respectively) or 0.65 ml of 0.88% NaCl twice a week. After 3 wk keratome biopsies were obtained from the treated plaques. Phospholipids extracted from the skin biopsies were separated into major classes by two-dimensional thin layer chromatography. 15-HETrE was then released from specific phospholipids after treatment with phospholipase A2 and identified by reverse phase and straight phase high preformance liquid chromatography. There was a dose-dependent incorporation of 15-HETrE into the specific phospholipids PI and PC. When expressed as ng 15-HETrE/ug phospholipid phosphate, 15-HETrE accumulated preferent-ically in PI. After injection of the highest 15-HETrE concentration, the mean amount of 15-HETrE estcrified in PI and PC was 81.9 ng/µg PI phosphate and 19.4 ng/µg PC phosphate, respectively. This incorporation of 15-HETrE incorporated into epidermal PLs was not accompanied by a clinical change of the treated psoriatic plaques. It remains to be determined whether higher 15-HETrE incorporated might induce clinical improvement of psoriasis.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1111/j.1600-0625.1995.tb00225.x
Permalink